DE1003781T1 - Interleukin-18 bindende proteine, deren herstellung und verwendung - Google Patents
Interleukin-18 bindende proteine, deren herstellung und verwendungInfo
- Publication number
- DE1003781T1 DE1003781T1 DE1003781T DE98938877T DE1003781T1 DE 1003781 T1 DE1003781 T1 DE 1003781T1 DE 1003781 T DE1003781 T DE 1003781T DE 98938877 T DE98938877 T DE 98938877T DE 1003781 T1 DE1003781 T1 DE 1003781T1
- Authority
- DE
- Germany
- Prior art keywords
- dna
- antibody
- protein
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000044166 interleukin-18 binding protein Human genes 0.000 title claims 35
- 108010070145 interleukin-18 binding protein Proteins 0.000 title claims 35
- 238000004519 manufacturing process Methods 0.000 title claims 4
- 108020004414 DNA Proteins 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 230000000903 blocking effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/834—Urine; urinary system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Claims (41)
1. IL-18-Bindungsprotein (IL-18BP), das die Aminosäuresequenz
von SEQ ID NO:10, Muteine, fusionierte Proteine, funktionelle Derivate, aktive Anteile, zirkulär permutierte Derivate und
Gemische davon enthält.
2. IL-18BP nach Anspruch 1, das mindestens eines aus dem Folgenden kann:
(i) Binden an IL-18,
(ii) Modulieren der Aktivität von IL-18, (iii) Blockieren der Aktivität von IL-18.
3. IL-18BP, ausgewählt aus der Gruppe, bestehend aus:
(a) Polypeptiden, die eine beliebige der Aminosäuresequenzen von SEQ ID NO:2, 4, 6 oder 8 umfassen;
(b) Polypeptid, wie in (a) definiert, ohne Leadersequenz,-
(c) Muteine, fusionierte Proteine, funktionelle Derivate,
aktive Anteile, zirkulär permutierte Derivate und 'Gemische davon der in (a) oder (b) definierten Polypeptide; und
(d) virale Homologe der in (a) oder (b) definierten Polypeptide.
4. IL-18BP nach Anspruch 3 mit mindestens einer der folgenden biologischen Eigenschaften:
(i) Binden an IL-18,
(ii) Modulieren der Aktivität von IL-18,
(iii) Blockieren der Aktivität von IL-18.
5. IL-18BP nach einem der Ansprüche 1-4, das ein nicht virales Protein ist.
6. IL-18BP nach Anspruch 5, das ein Humanprotein ist.
7. IL-18BP nach einem der Ansprüche 1-6 mit einem Molekulargewicht von etwa 40 kD.
8. IL-18BP nach einem der Ansprüche 1 bis 7, das ein
fusioniertes Protein ist.
9. Protein, das ein IL-18BP nach einem der Ansprüche 1 bis 8 umfaßt.
10. IL-18BP nach einem der Ansprüche 1 bis 9 in löslicher Form.
11. IL-18BP nach einem der Ansprüche 1 bis 10, das ein nichtglycosyliertes IL-18BP ist.
12. DNA, die unter stringenten Bedingungen hybridisieren kann
oder die Abgesehen von der Degeneration des genetischen Codes zur Hybridisierung unter stringenten Bedingungen in der Lage
wäre, mit mindestens einer der DNA-Sequenzen, die in SEQ ID NO:1, 3, 5 oder 7 gezeigt sind, wobei die DNA für-ein IL-18BP
nach einem der Ansprüche 1 bis 11 codieren kann.
13. DNA, die für ein IL-18BP nach einem der Ansprüche 1-11 codiert, einschließlich der Aminosäuresequenz von SEQ ID
NO:10.
14. DNA, die für ein IL-18BP nach einem der Ansprüche 1 bis 11 codiert, eischließlich der Aminosäuresequenz von SEQ ID NO:10,
·» ■« ♦·
DE/EP 1 0037Ö1T1
mit der Maßgabe eines Stopcodons an ihrem 3'-Ende.
15. DNA, die unter stringenten Bedingungen an die DNA von
Anspruch 13 hybridisiert oder die Abgesehen von der Degeneration des genetischen Codes zur Hybridisierung unter
stringenten Bedingungen in der Lage wäre, die für ein IL-18BP nach einem der Ansprüche 1-11 codieren kann.
16. DNA nach einem der Ansprüche 12 bis 15, die operativ an andere DNA-Sequenzen gebunden ist, die eine Expression
erleichtern, wie etwa Promotoren, Enhancer und dgl.
17. DNA nach einem der Ansprüche 12 bis 16, die eine genomische DNA ist.
18. DNA nach einem der Ansprüche 12 bis 17, die eine cDNA ist.
19. cDNA nach Anspruch 18, umfassend eine cDNA-Sequenz,
ausgewählt aus der Gruppe von DNA-Sequenzen von SEQ ID NO:1, 3, 5 und 7.
20. cDNA nach Anspruch 18 oder 19, die zur Expression in einem bakteriellen Wirt geeignet ist.
21. Replizierbares Expressionsvehikel, umfassend eine DNA nach einem der Ansprüche 12 bis 20.
22. Transformierte Wirtszelle, umfassend ein Expressionsvehikel nach Anspruch 21.
23. Transformierte Wirtszelle nach Anspruch 22, die eine
eukaryontische Zelle ist.
24. Transformierte Wirtszelle nach Anspruch 22, die eine prokariontische Zelle ist.
E/EP 1 QU3 /öl &mgr;
25. Verfahren zur Erzeugung von einem IL-18BP nach einem der Ansprüche 1 bis 11, umfassend das Kultivieren einer Wirtszelle
nach einem der Ansprüche 21 bis 23 unter Bedingungen, die zur Expression des IL-18BP geeignet sind und Isolieren des IL-18BP.
26. Antikörper gegen ein IL-18BP nach einem der Ansprüche bis 11.
27. Antikörper nach Anspruch 26, der ein polyklonaler Antikörper ist.
28. Antikörper nach Anspruch 26, der ein monoklonaler Antikörper ist.
29. Antikörper nach Anspruch 26, der ein antiidiotypischer Antikörper ist.
30. Antikörper nach Anspruch 26, der ein chimerer Antikörper
ist.
31. Antikörper nach Anspruch 26, der ein humanisierter Antikörper ist.
32. Verfahren zur Isolierung von einem IL-18BP nach Anspruch 3, umfassend:
(a) Leiten von Humanfluid durch eine Chromatographiesäule an welche IL-18 gekoppelt ist,
(b) Eluieren des Proteins, das an IL-18 binden kann,
(c) Reinigen des Proteins.
33. Pharmazeutische Zusammensetzung, umfassend ein IL-18BP nach einem der Ansprüche 1 bis
34. Pharmazeutische Zusammensetzung, umfassend ein
QjEiEP I 003 781 T1
viruscodiertes Homologes von einem IL-18BP nach einem der
Ansprüche 1 bis 11.
35. Pharmazeutische Zusammensetzung, umfassend eine DNA, die für ein IL-18BP nach einem der Ansprüche 1-11 codiert.
36. Verwendung eines IL-18BP nach einem der Ansprüche 1 bis bei der Herstellung einer pharmazeutischen Zusammensetzung zur
Behandlung von Krankheiten, die die Verabreichung von einem IL-18BP erfordern.
37. Verwendung eines viruscodierten Homlogen von einem IL-18BP nach einem der Ansprüche 1 bis 11 bei der Herstellung einer
pharmazeutischen Zusammensetzung zur Behandlung von Krankheiten, die die Verabreichung von einem IL-18BP
erfordern.
38. Verwendung von einem IL-18BP nach einem der Ansprüche 1 bis 11 zur Aufreinigung von einem IL-18.
39. Verwendung der Antikörper nach einem der Ansprüche 26 bis 31 in einem Assay zum Nachweis von einem IL-18BP.
40. Verwendung einer DNA, die für ein IL-18BP nach einem der Ansprüche 1 bis 11 codiert oder die ein viruscodiertes
Homologes des IL-18BP codiert, zur Gentherapie.
41. Verwendung einer DNA nach einem der Ansprüche · 12 bis 20 zum Herstellen eines IL-18BP nach einem der Ansprüche 1-11.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12155497A IL121554A0 (en) | 1997-08-14 | 1997-08-14 | Interleukin-18 binding proteins their preparation and use |
IL12163997A IL121639A0 (en) | 1997-08-14 | 1997-08-27 | Interleukin-18 binding proteins their preparation and use |
IL12186097A IL121860A0 (en) | 1997-08-14 | 1997-09-29 | Interleukin-18 binding proteins their preparation and use |
IL12213497A IL122134A0 (en) | 1997-08-14 | 1997-11-06 | Interleukin-18 binding proteins their preparation and use |
IL12546398A IL125463A0 (en) | 1997-08-14 | 1998-07-22 | Interleukin-18 binding proteins their preparation and use |
PCT/IL1998/000379 WO1999009063A1 (en) | 1997-08-14 | 1998-08-13 | Interleukin-18 binding proteins, their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1003781T1 true DE1003781T1 (de) | 2001-01-11 |
Family
ID=27517687
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841175T Expired - Lifetime DE69841175D1 (de) | 1997-08-14 | 1998-08-13 | Interleukin-18 bindende proteine, deren herstellung und verwendung |
DE1003781T Pending DE1003781T1 (de) | 1997-08-14 | 1998-08-13 | Interleukin-18 bindende proteine, deren herstellung und verwendung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841175T Expired - Lifetime DE69841175D1 (de) | 1997-08-14 | 1998-08-13 | Interleukin-18 bindende proteine, deren herstellung und verwendung |
Country Status (29)
Country | Link |
---|---|
US (4) | US6605280B1 (de) |
EP (1) | EP1003781B1 (de) |
JP (1) | JP4272348B2 (de) |
KR (1) | KR100687388B1 (de) |
CN (1) | CN1243021C (de) |
AR (2) | AR013422A1 (de) |
AT (1) | ATE443719T1 (de) |
AU (1) | AU755794B2 (de) |
BG (1) | BG65519B1 (de) |
BR (1) | BRPI9811940B8 (de) |
CA (1) | CA2298855C (de) |
CY (1) | CY1109664T1 (de) |
CZ (1) | CZ300818B6 (de) |
DE (2) | DE69841175D1 (de) |
DK (1) | DK1003781T3 (de) |
EA (1) | EA003675B1 (de) |
EE (1) | EE05538B1 (de) |
ES (1) | ES2149149T3 (de) |
HK (1) | HK1028773A1 (de) |
HU (1) | HU226698B1 (de) |
IL (5) | IL121860A0 (de) |
NO (1) | NO327240B1 (de) |
NZ (1) | NZ502392A (de) |
PL (1) | PL206070B1 (de) |
PT (1) | PT1003781E (de) |
SI (1) | SI1003781T1 (de) |
SK (1) | SK287194B6 (de) |
UA (1) | UA75862C2 (de) |
WO (1) | WO1999009063A1 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393663B2 (en) * | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
CA2340579A1 (en) * | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
IL131047A0 (en) | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
EP1101772B1 (de) * | 1999-11-16 | 2009-01-21 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Antikörper spezifisch für den Interleukin-18 Vorläufer |
TWI335336B (de) | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
EP1257292B1 (de) * | 2000-02-21 | 2011-04-27 | Merck Serono SA | Verwendung von il-18 inhibitoren |
AU2005211606B2 (en) * | 2000-05-05 | 2007-02-22 | Inserm - Institut National De La Sante Et De La Recherche Medicale | Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis |
UA87658C2 (uk) * | 2000-05-05 | 2009-08-10 | Апплайд Резеч Системз Арс Холдинг Н.В. | Застосування il-18 як діагностичного маркера серцевої недостатності |
EP1331943A4 (de) * | 2000-10-11 | 2005-01-26 | Viron Therapeutics Inc | Nukleinsäure-moleküle und polypeptide zur immunmodulation |
US7718368B2 (en) * | 2000-12-04 | 2010-05-18 | Viron Therapeutics Inc. | Immunomodulatory protein and useful embodiments thereof |
KR100857376B1 (ko) * | 2001-01-29 | 2008-09-05 | 라보라토리스 세로노 에스.에이. | 심장 질환의 치료 및/또는 예방에 사용되는 il-18저해물질 |
MXPA03010575A (es) * | 2001-05-16 | 2005-03-07 | Yeda Res & Dev | Uso de inhibidores de il-08 para el tratamiento o prevencion de sepsis. |
KR20040030625A (ko) * | 2001-05-25 | 2004-04-09 | 아레스 트레이딩 에스.에이. | Cns 손상을 치료하거나 예방하기 위한 il-18저해물질의 용도 |
EP2087908B1 (de) | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antikörper gegen opgl |
UA78516C2 (en) * | 2001-08-10 | 2007-04-10 | Applied Research Systems | Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity |
BRPI0308663B8 (pt) * | 2002-03-22 | 2021-05-25 | Applied Res Systems Ars Holding N V | uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas |
PL376536A1 (pl) | 2002-08-28 | 2006-01-09 | Immunex Corporation | Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego |
MXPA05003869A (es) * | 2002-10-08 | 2005-06-22 | Ares Trading Sa | El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina. |
IL152232A0 (en) * | 2002-10-10 | 2003-05-29 | Yeda Res & Dev | Promoter to il-18bp, its preparation and use |
EP1621616A4 (de) | 2003-04-30 | 2007-07-04 | Japan Science & Tech Agency | Menschlicher anti-mensch-interleukin-18-antikörper, fragment davon und verfahren zu deren verwendung |
JP5074030B2 (ja) * | 2003-05-13 | 2012-11-14 | メルク セローノ ソシエテ アノニム | Il−18結合タンパク質の活性変異体とその医学的応用 |
ME01198B (me) | 2003-11-05 | 2013-03-20 | Ares Trading Sa | Prečišćavanje il-18 vezujućeg proteina |
US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
WO2005047478A2 (en) * | 2003-11-12 | 2005-05-26 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for regulation of tumor necrosis factor-alpha |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
IL159670A0 (en) * | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
ATE375385T1 (de) * | 2004-03-01 | 2007-10-15 | Ares Trading Sa | Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen |
WO2005097998A2 (en) * | 2004-03-31 | 2005-10-20 | Regeneron Pharmaceuticals, Inc. | Il-18 specific polypeptides and therapeutic uses thereof |
WO2006003134A1 (en) * | 2004-06-29 | 2006-01-12 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
JP5048658B2 (ja) * | 2005-06-03 | 2012-10-17 | メルク セローノ ソシエテ アノニム | 神経性炎症性疾患の治療、及び/又は予防のためのil−18bpアイソフォームの使用 |
DK2267024T3 (da) * | 2005-06-03 | 2012-06-25 | Ares Trading Sa | Fremstilling af rekombinant II-18 bindingsprotein |
PL1891088T3 (pl) * | 2005-06-10 | 2012-03-30 | Ares Trading Sa | Sposób oczyszczania białka wiążącego IL-18 |
CN101003812B (zh) * | 2006-01-17 | 2011-01-05 | 温州医学院 | 一种用于制备重组人egf-il18融合蛋白的方法 |
JP5420399B2 (ja) | 2006-05-25 | 2014-02-19 | グラクソ グループ リミテッド | 改変型ヒト化抗インターロイキン−18抗体 |
WO2010040736A2 (en) * | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
CA2897067A1 (en) * | 2013-01-02 | 2014-07-10 | Wilsa, Inc. | Method and apparatus for conditioning fluids |
MX2016002719A (es) | 2013-09-05 | 2016-09-06 | Ab2 Bio Sa | Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias. |
MY194040A (en) | 2015-03-05 | 2022-11-09 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
EP3943097A1 (de) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t-zelltherapie |
WO2023143535A1 (zh) * | 2022-01-28 | 2023-08-03 | 和径医药科技(上海)有限公司 | 一种靶向il-18bp的抗体及其应用 |
WO2023178192A1 (en) * | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
CN114605521A (zh) * | 2022-04-06 | 2022-06-10 | 内蒙古农业大学 | 一种细胞免疫调节蛋白及其应用 |
CN114891125B (zh) * | 2022-06-16 | 2023-04-11 | 广东医科大学 | 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985863A (en) | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
GB9214857D0 (en) * | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
US5776731A (en) | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
AU4959997A (en) | 1996-11-15 | 1998-06-10 | Kennedy Institute Of Rheumatology, The | Suppression of tnf alpha and il-12 in therapy |
DE69736984T2 (de) | 1996-12-06 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren des interleukin-1-beta konvertierenden enzyms |
US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
US6087116A (en) | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
CA2282845A1 (en) | 1997-03-18 | 1998-09-24 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
EP1000147A2 (de) | 1997-08-01 | 2000-05-17 | Serono Genetics Institute S.A. | 5' ests für sekretierte proteine, die im hoden und anderen geweben exprimiert werden |
CA2296844A1 (en) | 1997-08-01 | 1999-02-11 | Genset | 5' ests for secreted proteins expressed in various tissues |
IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
CZ298579B6 (cs) | 1998-04-28 | 2007-11-14 | Applied Research Systems Ars Holding N. V. | Konjugát polyolu a interferonu-beta |
CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
CA2340579A1 (en) | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
WO2001019373A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
-
1997
- 1997-09-29 IL IL12186097A patent/IL121860A0/xx unknown
- 1997-11-06 IL IL12213497A patent/IL122134A0/xx unknown
-
1998
- 1998-07-22 IL IL12546398A patent/IL125463A0/xx unknown
- 1998-08-13 SK SK176-2000A patent/SK287194B6/sk not_active IP Right Cessation
- 1998-08-13 AT AT98938877T patent/ATE443719T1/de active
- 1998-08-13 CZ CZ20000490A patent/CZ300818B6/cs not_active IP Right Cessation
- 1998-08-13 ES ES98938877T patent/ES2149149T3/es not_active Expired - Lifetime
- 1998-08-13 DE DE69841175T patent/DE69841175D1/de not_active Expired - Lifetime
- 1998-08-13 DE DE1003781T patent/DE1003781T1/de active Pending
- 1998-08-13 AU AU87460/98A patent/AU755794B2/en not_active Expired
- 1998-08-13 BR BRPI9811940 patent/BRPI9811940B8/pt not_active IP Right Cessation
- 1998-08-13 DK DK98938877.2T patent/DK1003781T3/da active
- 1998-08-13 HU HU0003533A patent/HU226698B1/hu unknown
- 1998-08-13 EA EA200000216A patent/EA003675B1/ru not_active IP Right Cessation
- 1998-08-13 IL IL13452398A patent/IL134523A0/xx active IP Right Grant
- 1998-08-13 UA UA2000031437A patent/UA75862C2/uk unknown
- 1998-08-13 EE EEP200000073A patent/EE05538B1/xx unknown
- 1998-08-13 CA CA2298855A patent/CA2298855C/en not_active Expired - Lifetime
- 1998-08-13 WO PCT/IL1998/000379 patent/WO1999009063A1/en not_active Application Discontinuation
- 1998-08-13 SI SI9830922T patent/SI1003781T1/sl unknown
- 1998-08-13 EP EP98938877A patent/EP1003781B1/de not_active Expired - Lifetime
- 1998-08-13 KR KR1020007001504A patent/KR100687388B1/ko not_active IP Right Cessation
- 1998-08-13 PT PT98938877T patent/PT1003781E/pt unknown
- 1998-08-13 PL PL338647A patent/PL206070B1/pl unknown
- 1998-08-13 NZ NZ502392A patent/NZ502392A/xx not_active IP Right Cessation
- 1998-08-13 CN CNB988081342A patent/CN1243021C/zh not_active Expired - Lifetime
- 1998-08-13 US US09/485,632 patent/US6605280B1/en not_active Expired - Lifetime
- 1998-08-13 JP JP2000509740A patent/JP4272348B2/ja not_active Expired - Lifetime
- 1998-08-14 AR ARP980104054A patent/AR013422A1/es active IP Right Grant
-
2000
- 2000-02-10 BG BG104149A patent/BG65519B1/bg unknown
- 2000-02-11 NO NO20000700A patent/NO327240B1/no not_active IP Right Cessation
- 2000-02-13 IL IL134523A patent/IL134523A/en not_active IP Right Cessation
- 2000-12-19 HK HK00108180A patent/HK1028773A1/xx not_active IP Right Cessation
-
2003
- 2003-05-08 US US10/434,583 patent/US7101689B2/en not_active Expired - Lifetime
-
2006
- 2006-03-15 US US11/376,794 patent/US7799541B2/en not_active Expired - Fee Related
-
2007
- 2007-09-17 AR ARP070104104A patent/AR062867A2/es not_active Application Discontinuation
-
2009
- 2009-07-29 US US12/511,756 patent/US8436148B2/en not_active Expired - Fee Related
- 2009-11-25 CY CY20091101232T patent/CY1109664T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1003781T1 (de) | Interleukin-18 bindende proteine, deren herstellung und verwendung | |
DE69434053T2 (de) | Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität | |
DE69028671T3 (de) | Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung | |
DE69824755T2 (de) | Cytokinähnliches polypeptid-10 aus säugetieren | |
DE69630710T2 (de) | Humaner tumornekrosefaktor delta und epsilon | |
DE69017753T3 (de) | Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper | |
DE69824719T2 (de) | Cytokinähnlicher faktor-7 aus säugetieren | |
DE69531892T2 (de) | Fibroblasten-wachstumsfaktor 10 | |
DE69532436T2 (de) | Einzelkettenformen des clycoprotein-hormon-quartetts | |
DE68908633T2 (de) | Polypeptide mit zellenverstreuender Aktivität. | |
WO1995003328A2 (de) | Melanom-inhibierendes protein | |
DE69926627T2 (de) | Insulinartigen wachstumsfaktor bindendes protein -3 variante | |
DE69505804T2 (de) | Afamin: ein menschliches serum albumin ähnliches protein | |
EP0875567A2 (de) | Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung | |
DE69132813T2 (de) | Genetisches igfbp-5 rodierendes material | |
Inoue et al. | Neuron-specific antigen HPC-1 from bovine brain reveals strong homology to epimorphin, an essential factor involved in epithelial morphogenesis: identification of a novel protein family | |
DE69732350T2 (de) | Persephin und verwandte wachstumsfaktoren | |
DE69522492T2 (de) | Verfahren zur Herstellung von Alpha-Interferon | |
DE69333063T2 (de) | Vekürztes insulinähnlichen wachstumsfaktor-bindendes protein mit mitogener aktivität | |
DE69532874T2 (de) | RPDL Protein und kodierende DNS | |
DE69131979T2 (de) | Genetisches igfbp-4 rodierendes material | |
DE3536939A1 (de) | Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten | |
DE69233155T2 (de) | Insulinartigen wachstumsfaktor bindendes protein | |
CA2128215C (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy | |
DE68923496T2 (de) | Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression. |